Alexion Pharmaceuticals Inc

Alexion Pharmaceuticals Inc is a leading biopharmaceutical company that specializes in developing and commercializing innovative therapies for patients with rare and severe diseases. With a mission to transform the lives of patients, Alexion's portfolio of products includes Soliris and Ultomiris, which are treatments for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The company is dedicated to advancing the science of complement biology to develop new therapies for patients with rare and severe diseases. Headquartered in Boston, Massachusetts, Alexion operates in over 50 countries worldwide. The company is committed to making a meaningful difference in the lives of patients and their families, while also being a responsible corporate citizen by supporting the communities in which it operates.